164 related articles for article (PubMed ID: 32633605)
1. What does first-line therapy mean for paediatric multiple sclerosis in the current era?
Hacohen Y; Banwell B; Ciccarelli O
Mult Scler; 2021 Nov; 27(13):1970-1976. PubMed ID: 32633605
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis.
Yeh EA; Weinstock-Guttman B; Ramanathan M; Ramasamy DP; Willis L; Cox JL; Zivadinov R
Brain; 2009 Dec; 132(Pt 12):3392-400. PubMed ID: 19892770
[TBL] [Abstract][Full Text] [Related]
3. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
5. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
Kopp TI; Blinkenberg M; Chalmer TA; Petersen T; Ravnborg MH; Soelberg Sørensen P; Magyari M
Mult Scler; 2020 Jul; 26(8):964-975. PubMed ID: 31081451
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Treatment of Multiple Sclerosis: A Review.
McGinley MP; Goldschmidt CH; Rae-Grant AD
JAMA; 2021 Feb; 325(8):765-779. PubMed ID: 33620411
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
8. Differences and similarities in the evolution of morphologic brain abnormalities between paediatric and adult-onset multiple sclerosis.
Pichler A; Enzinger C; Fuchs S; Plecko-Startinig B; Gruber-Sedlmayr U; Linortner P; Langkammer C; Khalil M; Ebner F; Ropele S; Fazekas F
Mult Scler; 2013 Feb; 19(2):167-72. PubMed ID: 22717380
[TBL] [Abstract][Full Text] [Related]
9. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Johnston J; So TY
Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
11. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E;
Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005
[TBL] [Abstract][Full Text] [Related]
12. Optimizing treatment success in multiple sclerosis.
Ziemssen T; Derfuss T; de Stefano N; Giovannoni G; Palavra F; Tomic D; Vollmer T; Schippling S
J Neurol; 2016 Jun; 263(6):1053-65. PubMed ID: 26705122
[TBL] [Abstract][Full Text] [Related]
13. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
[TBL] [Abstract][Full Text] [Related]
14. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
Filippi M; Amato MP; Centonze D; Gallo P; Gasperini C; Inglese M; Patti F; Pozzilli C; Preziosa P; Trojano M
J Neurol; 2022 Oct; 269(10):5382-5394. PubMed ID: 35608658
[TBL] [Abstract][Full Text] [Related]
15. INNOVATIVE THERAPIES REDEFINE TREATMENT GOALS IN MULTIPLE SCLEROSIS.
Lazibat I; Šamija RK; Rotim K
Acta Clin Croat; 2016 Mar; 55(1):125-33. PubMed ID: 27333728
[TBL] [Abstract][Full Text] [Related]
16. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
17. Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis.
Fahrbach K; Huelin R; Martin AL; Kim E; Dastani HB; Rao S; Malhotra M
BMC Neurol; 2013 Nov; 13():180. PubMed ID: 24245966
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.
Janardhan V; Bakshi R
Arch Neurol; 2000 Oct; 57(10):1485-91. PubMed ID: 11030802
[TBL] [Abstract][Full Text] [Related]
19. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis in Belgian children: A multicentre retrospective study.
Verhelst H; De Waele L; Deconinck N; Ceulemans B; Willekens B; Van Coster R
Eur J Paediatr Neurol; 2017 Mar; 21(2):358-366. PubMed ID: 27818023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
